[Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs 
in Non-small Cell Lung Cancer].

ABSTRACT: Most non-small cell lung cancer patients with active epidermal growth factor receptor (EGFR) mutation will eventually acquire drug resistant to EGFR tyrosine kinase inhibitors, such as gefitinib, resulting in disease progression, which involves a variety of complex mechanisms. Up to now, the molecular mechanisms of long non-coding RNAs mediated EGFR-TKIs resistance remains poorly understood. This review aims to outline the current state of information on lncRNAs and progress on its role in EGFR-TKIs resistance in non-small cell lung cancer.

SUBMITTER: Li S 

PROVIDER: S-EPMC5973017 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature